SBI Securities’s ImmunityBio IBRX Stock Holding History

SBI Securities’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19M	Sell	136,321 -20,283	-13%	-$154K	0.03%	261
2026 Q1	$1.2M	Buy	156,604 +37,282	+31%	+$255K	0.03%	243
2025 Q4	$236K	Buy	119,322 +6,016	+5%	+$13.6K	0.01%	581
2025 Q3	$279K	Sell	113,306 -4,763	-4%	-$12.3K	0.01%	540
2025 Q2	$312K	Buy	118,069 +105,292	+824%	+$283K	0.01%	462
2025 Q1	$38.5K	Sell	12,777 -9,900	-44%	-$30K	﹤0.01%	1073
2024 Q4	$58.1K	Buy	+22,677	New	+$94.5K	﹤0.01%	931

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SBI Securities's IBRX Position: Q2 2026 in Review

SBI Securities reduced its ImmunityBio (IBRX) stake by 13% in Q2 2026, selling an estimated $154K and leaving 136,321 shares worth $1.19M. The position accounts for 0.03% of the portfolio, ranked #261.

SBI Securities first reported a position in IBRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.2M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

SBI Securities held 136,321 shares of ImmunityBio worth $1.19M as of Q2 2026.
SBI Securities sold 20,283 ImmunityBio shares in Q2 2026, an estimated $154K.
ImmunityBio made up 0.03% of SBI Securities's portfolio in Q2 2026, its #261 holding.
SBI Securities first reported a position in ImmunityBio in Q4 2024 and has held it in 7 quarters since.
SBI Securities's ImmunityBio position peaked at $1.2M in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.